NAV

FET F-18

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
FET F-18
DrugBank Accession Number
DB15405
Background

FET F-18 is under investigation in clinical trial NCT01756352 (FET-PET for Evaluation of Response of Recurrent GBM to Avastin).

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 226.238
Monoisotopic: 226.098305982
Chemical Formula
C11H14FNO3
Synonyms
  • 18F-FET
  • FLUOROETHYL-L-TYROSINE (18F)
  • O-(2-FLUOROETHYL)-L-TYROSINE F-18
  • O-18F-fluoroethyl-L-tyrosine
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

ATC Codes
V09IX10 — Fluoroethyl-l-tyrosine (18f)
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
1326R5J1IA
CAS number
178433-03-9
InChI Key
QZZYPHBVOQMBAT-LRAGLOQXSA-N
InChI
InChI=1S/C11H14FNO3/c12-5-6-16-9-3-1-8(2-4-9)7-10(13)11(14)15/h1-4,10H,5-7,13H2,(H,14,15)/t10-/m0/s1/i12-1
IUPAC Name
(2S)-2-amino-3-{4-[2-(¹⁸F)fluoroethoxy]phenyl}propanoic acid
SMILES
N[C@@H](CC1=CC=C(OCC[18F])C=C1)C(O)=O

References

General References
Not Available
ChemSpider
8010200
ChEMBL
CHEMBL477278
ZINC
ZINC000101627026

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingDiagnosticBrain Neoplasm / Low-Grade Glioma / Recurrent Glioblastoma / Recurrent WHO Grade III Glioma / Recurrent World Health Organization (WHO) Grade II Glioma1
2CompletedDiagnosticGlioblastoma Multiforme (GBM) / High Grade Glioma: Glioblastoma (GBM)1
1RecruitingTreatmentGlioblastoma Multiforme (GBM) / High Grade Glioma: Glioblastoma (GBM) / Neoplasm1
Not AvailableRecruitingNot AvailableGlioma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.47 mg/mLALOGPS
logP-1.7ALOGPS
logP-1.1Chemaxon
logS-2ALOGPS
pKa (Strongest Acidic)1.93Chemaxon
pKa (Strongest Basic)9.47Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area72.55 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity56.18 m3·mol-1Chemaxon
Polarizability22.52 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-01s9-0940000000-c94bc114ebc1061ec071
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-06si-3950000000-b1f42dae5a0e74cbdcb3
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-014r-0900000000-a3642ce4677991ab76aa
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-9200000000-ac15abbb84a0ff2a004e
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-01x3-4900000000-457efb428aca5a179e85
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-014l-5900000000-6455a854e9650be5d9f4
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at May 20, 2019 15:25 / Updated at July 18, 2023 22:57